|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2004-11-9
|
|
pubmed:abstractText |
Attaining hepatitis B e antigen (HBeAg) seroconversion during lamivudine treatment is associated with fewer relapses in HBeAg-positive patients. In HBeAg-negative patients, predictors for post-treatment relapse remain largely unknown. We therefore studied whether end-of-treatment virologic response correlated with relapse after lamivudine treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1007-9327
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3574-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15534909-Adult,
pubmed-meshheading:15534909-DNA, Viral,
pubmed-meshheading:15534909-Female,
pubmed-meshheading:15534909-Follow-Up Studies,
pubmed-meshheading:15534909-Genotype,
pubmed-meshheading:15534909-Hepatitis B, Chronic,
pubmed-meshheading:15534909-Hepatitis B virus,
pubmed-meshheading:15534909-Humans,
pubmed-meshheading:15534909-Lamivudine,
pubmed-meshheading:15534909-Male,
pubmed-meshheading:15534909-Middle Aged,
pubmed-meshheading:15534909-Predictive Value of Tests,
pubmed-meshheading:15534909-Prospective Studies,
pubmed-meshheading:15534909-Recurrence,
pubmed-meshheading:15534909-Reverse Transcriptase Inhibitors,
pubmed-meshheading:15534909-Treatment Outcome,
pubmed-meshheading:15534909-Viral Load
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.
|
|
pubmed:affiliation |
Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, China.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
